

NCCOR

CONNECT
& EXPLORE

1. Welcome


2. Spotlight

- Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity
- CDC Extended BMI-for-age Growth Charts

3. Q & A

4. NCCOR Announcements

TODAY'S PROGRAM



Today's Speakers



Karen Hilyard, PhD
Moderator



Sarah Hampl, MD, FAAP
University of Missouri-Kansas City
School of Medicine




Sandra Hassink, MD, FAAP
American Academy of Pediatrics
Institute for Healthy
Childhood Weight



Cynthia Ogden, PhD
U.S. Centers for Disease
Control and Prevention

Have a question for our speakers?

Type your question(s) by clicking the Q&A icon located below and a representative will respond shortly.






**Join the conversation on social media
#ConnectExplore**

Follow @NCCOR

INTERACTIVE POLL



SPOTLIGHT



Evaluation and Treatment of Children and Adolescents with Obesity

An AAP Clinical Practice Guideline

Sandra G. Hassink, MD, FAAP, Medical Director, AAP Institute for Healthy Childhood Weight


Sarah E. Hampl, MD, FAAP, DABOM, Children's Mercy Kansas City Center for Children's Healthy Lifestyles & Nutrition; University of MO-Kansas City School of Medicine

Disclosures

- We served as the vice-chair and chair of the “Evaluation and Treatment of Children and Adolescents with Obesity” CPG writing committee.
- Sandra is the Medical Director of the AAP Institute for Healthy Childhood Weight.

Youth

Trends in obesity among children and adolescents ages 2–19 years, by age: United States, 1963–1965 through 2017–2018³



<https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity>

Copyright protected material

NCCOR
CONNECT
& EXPLORE

14.1



Million children and adolescents in the United States are affected by obesity



Looking Back – 1997

March 1997
2-day Meeting
Convened by
HRSA

20
Organizational &
Institute
Representatives
Attended

Expert Committee:

William H. Dietz, MD, PhD

Leonard H. Epstein, PhD

Samuel S. Gidding, MD

John H. Himes, PhD, MPH

Linda Jonides, RN, CPNP

William J. Klish, MD

Thomas N. Robinson MD, MPH

Mary Story, PhD, RD

Sarah Barlow attended and wrote manuscript with references

16 multidisciplinary specialists (physicians, dietitians, nurses, psychologists) reviewed the draft

PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Pediatrics 2007;120;Supplement 163-288

**Expert Committee Recommendations Regarding the Prevention, Assessment,
and Treatment of Child and Adolescent Overweight and Obesity: Summary
Report**

Sarah E. Barlow and the Expert Committee

Assessment of Child and Adolescent Overweight and Obesity

Nancy F. Krebs, John H. Himes, Dawn Jacobson, Theresa A. Nicklas, Patricia
Guilday and Dennis Styne

Recommendations for Prevention of Childhood Obesity

Matthew M. Davis, Bonnie Gance-Cleveland, Sandra Hassink, Rachel Johnson, Gilles
Paradis and Kenneth Resnicow

**Recommendations for Treatment of Child and Adolescent Overweight and
Obesity**

Bonnie A. Spear, Sarah E. Barlow, Chris Ervin, David S. Ludwig, Brian E. Saelens,
Karen E. Schetzina and Elsie M. Taveras

CPG Development



Comprehensive Process

2017



CPG By the Numbers

15
Years Since Last
Comprehensive
Guidance

**16K Abstracts
Reviewed**



1642
Full Text
Articles



382
Studies
Included



13
CPG Key Action
Statements



11
CPG Consensus
Recommendations



2
Technical
Reports

Methodology – Scope of the Review

Key Question 1

What are clinic-based, effective treatments for obesity?

Key Question 2

What is the risk of comorbidities among children with obesity?

Original search period ended April 6, 2018.
An additional search was conducted covering the time period April 7, 2018 - February 15, 2020.

- 15 988 Articles screened
- 1642 Full text articles reviewed
- 382 Studies included

Inclusion Criteria for Both Key Questions

- Required to include children ages 2-18 years.
- Children could have other conditions (e.g., asthma) as long as they were not known to cause obesity, such as Prader-Willi syndrome, obesogenic medication (e.g., antipsychotics), or known genetic mutations associated with obesity (e.g., MC4R).
- All studies had to originate from Organization for Economic Cooperation and Development (OECD) member countries and had to be available in English.

Evidence Grading for Key Action Statement (KAS) Development

AGGREGATE EVIDENCE QUALITY	BENEFIT OR HARM PREDOMINATES	BENEFIT AND HARM BALANCED
LEVEL A Intervention: Well designed and conducted trials, meta-analyses on applicable populations Diagnosis: Independent gold standard studies of applicable populations	STRONG RECOMMENDATION	WEAK RECOMMENDATION (based on balance of benefit and harm)
LEVEL B Trials or diagnostic studies with minor limitations; consistent findings from multiple observational studies	MODERATE RECOMMENDATION	
LEVEL C Single or few observational studies or multiple studies with inconsistent findings or major limitations.	WEAK RECOMMENDATION (based on low quality evidence)	No recommendation may be made.
LEVEL D Expert opinion, case reports, reasoning from first principles		
LEVEL X Exceptional situations where validating studies cannot be performed and benefit or harm clearly predominates	STRONG RECOMMENDATION MODERATE RECOMMENDATION	



“
The CPG summarizes what we know about child obesity treatment and comorbidity management and provides practical, effective recommendations in the context of whole-child care, non-stigmatizing communication, and addresses key social drivers of health.

- Sarah Armstrong, MD, FAAP

”

New From Previous Recommendations

- We understand more fully the implications of obesity as a **chronic disease**.
- We understand the physiological impacts of **social determinants of health** on obesity more completely.
- We know more fully that **weight bias and stigma** is pervasive and harmful, and it can be a barrier to treatment.

New From Previous Recommendations

- Offer treatment early and immediately – **there is no benefit to watchful waiting.**
- Treat obesity and comorbid conditions **concurrently.**
- There are **multiple evidence-based strategies** that can be used collectively to deliver intensive & tailored obesity treatment.
- **Structured, supervised weight management** interventions **decrease current & future eating disorder symptoms.**

New From Previous Recommendations

- Obesity is often an **indicator of structural inequities** like unjust food systems, health inequities and environmental & community factors
- Genetics, obesity-promoting environments, life experiences combined with inequities and structural barriers to healthy living **all contribute to overweight and obesity.**

Social and Environmental Context


Comorbidity Risk


- We now recognize that race is not a biological construct.
- So, the association between
 - ethnicity,
 - race,
 - obesity, and
 - comorbidities

most likely reflects the impact of epigenetic, social, and environmental factors, such as SDOH (e.g., limited food access, low SES, exposure to structural racism, neighborhood deprivation, etc.).

Key Takeaways


 Obesity is a complex chronic disease

 There are effective evidence-based strategies for treatment

 Comprehensive whole child evaluations are important

 Treating obesity also means treating comorbidities

 Obesity treatment is safe and effective


 Children with overweight or obesity should be offered treatment upon diagnosis

Whole Child Approach

Underlying **genetic, biological, environmental,** and **social determinants** that are risks for obesity is the foundation of evaluation and treatment.

- AAP Clinical Practice Guideline

Treatment Experience of Obesity as a Chronic Disease



“The primary care clinician is well-positioned to evaluate for weight-related comorbidities, appropriately initiate treatment, coordinate care with subspecialists, and provide concurrent obesity and comorbidity treatment.

- CPG

”





Evaluation Recommendations

Assessment & Evaluation KAS Topics



BMI Measurement



Comprehensive Evaluation
(PE, ROS, Hx, etc)



Risk Assessment
(Whole child)



Comorbidity Evaluation
(labs, tests)

BMI Measurement

KAS 1. Pediatricians and other PHCPs should measure height and wt, calculate BMI, and assess BMI percentile using age- and sex-specific CDC growth charts or growth charts for children with severe obesity at least annually for all children 2 to 18 y of age to screen for overweight (BMI ≥ 85 th percentile to < 95 th percentile), obesity (BMI ≥ 95 th percentile), and severe obesity (BMI $\geq 120\%$ of the 95th percentile for age and sex).

Assess Risk

- Consensus Recommendation: Perform initial and longitudinal assessment of individual, structural, and contextual risk factors to provide individualized and tailored treatment of the child/adolescent with overweight/obesity.

Comorbidities

- There is compelling evidence that obesity increases the risk for comorbidities, and that weight loss interventions can improve comorbidities. - CPG



Evaluate for Comorbid Conditions

KAS 2. Pediatricians and other PHCPs should evaluate children 2 to 18 y of age with overweight (BMI \geq 85th percentile to $<$ 95th percentile) and obesity (BMI \geq 95th percentile) for obesity-related comorbidities by using a comprehensive patient history, mental and behavioral health screening, SDoH evaluation, physical examination, and diagnostic studies.

Lab Evaluation

KAS 3.1. In children 10 y and older with overweight (BMI \geq 85th percentile to $<$ 95th percentile), pediatricians and other PHCPs may evaluate for abnormal glucose metabolism and liver function in the presence of risk factors for T2DM or NAFLD. In children 2 to 9 y of age with obesity (BMI \geq 95th percentile), pediatricians and other PHCPs may evaluate for lipid abnormalities.

KAS 5. Pediatricians and other PHCPs should evaluate for dyslipidemia by obtaining a fasting lipid panel in children 10 y and older with overweight (BMI \geq 85th percentile to $<$ 95th percentile) and obesity (BMI \geq 95th percentile) and may evaluate for dyslipidemia in children 2 through 9 y of age with obesity.

KAS 6. Pediatricians and other PHCPs should evaluate for prediabetes and/or diabetes mellitus with fasting plasma glucose, 2-h plasma glucose after 75-g oral glucose tolerance test (OGTT), or glycosylated hemoglobin (HbA1c)


KAS 7. Pediatricians and other PHCPs should evaluate for NAFLD by obtaining an alanine transaminase (ALT) test.

KAS 8. Pediatricians and other PHCPs should evaluate for hypertension by measuring blood pressure at every visit starting at 3 y of age in children and adolescents with overweight (BMI \geq 85 to $<$ 95th percentile) and obesity (BMI \geq 95th percentile).

Consensus Recommendations for Other Comorbid Conditions

Comorbid Condition	Consensus Recommendation
OSA	<ul style="list-style-type: none">• Obtain a sleep history, including symptoms of snoring, daytime somnolence, nocturnal enuresis, morning headaches, and inattention, among children and adolescents with obesity to evaluate for OSA.• Obtain a polysomnogram for children and adolescents with obesity and at least one symptom of disordered breathing.
PCOS	<ul style="list-style-type: none">• Evaluate for menstrual irregularities and signs of hyperandrogenism (ie, hirsutism, acne) among female adolescents with obesity to assess risk for PCOS.
Depression	<ul style="list-style-type: none">• Monitor for symptoms of depression in children and adolescents with obesity and conduct annual evaluation for depression for adolescents 12 years and older with a formal self-report tool.
Blount	<ul style="list-style-type: none">• Perform a musculoskeletal review of systems and physical examination (eg, internal hip rotation in growing child, gait) as part of their evaluation for obesity.
SCFE	<ul style="list-style-type: none">• Recommend immediate and complete activity restriction, non-weight-bearing with use of crutches, and refer to an <u>orthopaedic surgeon</u> for emergent evaluation, if SCFE is suspected. PHCPs may consider sending the child to an emergency department if an <u>orthopaedic surgeon</u> is not available.
IIH	<ul style="list-style-type: none">• Maintain a high index of suspicion for IIH with new-onset or progressive headaches in the context of significant weight


Algorithm for Screening, Diagnosis, Evaluation, and Treatment of Pediatric Overweight and Obesity



Algorithm: Supports clinical decisions for screening, diagnosing, evaluating and treating pediatric obesity at the point of care.

Clinical Flow: Assessment and Evaluation

Consistent with the 2023 AAP Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Overweight & Obesity.



Obtain Comprehensive Obesity-specific Patient History

Assess individual, structural, and contextual risk and protective factors related to healthy behavior and healthy weight, including: medical history (chief complaint/history of present illness, review of systems, medication history, family history), social determinants of health, individual/family lifestyle behavior history, and mental and behavioral health.

Review of Systems - Relevant Findings		History Components & Possible Tools											
System	Symptoms of Obesity-related Conditions	Chief Complaint/History of Present Illness: To determine if obesity is of concern and understand its trajectory											
General	Poor/slowed linear growth velocity, hyperphagia from early childhood, developmental delay, obesity onset <age 5 years or syndromic features	Family History (Obtain all for 1st & 2nd degree relatives): Obesity, type 2 diabetes, cardiovascular disease, hyperlipidemia, hypertension, NAFLD											
Respiratory	Shortness of breath, snoring, apnea, disordered sleep	Medication History: Evaluate for obesogenic medications and possible alternatives											
Gastrointestinal	Asymptomatic vague abdominal pain, heartburn, dysphagia, chest pain, regurgitation, abdominal pain, enuresis, encopresis, anorexia, right upper quadrant pain; hyperphagia	<table border="1"> <thead> <tr> <th>Components</th> <th>Tools</th> </tr> </thead> <tbody> <tr> <td>Social Determinants of Health</td> <td> <ul style="list-style-type: none"> Food security, economic security, & other social determinants of health (e.g., ACES) Safe Environment for Every Kid (SEEK) Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool </td> </tr> <tr> <td>Individual/Family Lifestyle Behavior</td> <td> <ul style="list-style-type: none"> Nutrition: eating out, sugar-sweetened beverages, portions, snack habits Physical activity: motivation/knowledge/competence to engage in physical activity Recreational screen time Sleep </td> <td> <ul style="list-style-type: none"> Overall: MaineHealth Let's Go! 5-2-1-0-Healthy-Habits-Questionnaires Nutrition: Written, electronic, or phone/text-prompted food diaries, 24-hour recall, smartphone tracking applications Physical Activity: Pedometers or other wearable activity monitors </td> </tr> <tr> <td>Mental & Behavioral Health</td> <td> <ul style="list-style-type: none"> Depression: Monitor for symptoms; if ≥12 years old evaluate annually using a formal self-report tool Other mental health: bullying, anxiety, abuse, ADHD Disordered eating: skipping meals, using diet pills/laxatives, inducing vomiting, restricting intake, binge-eating, etc. </td> <td> <ul style="list-style-type: none"> Overall: Pediatric Symptom Checklist Depression: Patient Health Questionnaire (PHQ 2 or 9) Anxiety: General Anxiety Disorder (GAD-7) or Screen for Child Anxiety Related Disorders (SCARED) assessments ADHD: Vanderbilt ADHD Rating Scales (VADRS) Disordered eating: Table 2, AAP Clinical report, "Identification and Management of Eating Disorders in Children and Adolescents" </td> </tr> </tbody> </table>		Components	Tools	Social Determinants of Health	<ul style="list-style-type: none"> Food security, economic security, & other social determinants of health (e.g., ACES) Safe Environment for Every Kid (SEEK) Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool 	Individual/Family Lifestyle Behavior	<ul style="list-style-type: none"> Nutrition: eating out, sugar-sweetened beverages, portions, snack habits Physical activity: motivation/knowledge/competence to engage in physical activity Recreational screen time Sleep 	<ul style="list-style-type: none"> Overall: MaineHealth Let's Go! 5-2-1-0-Healthy-Habits-Questionnaires Nutrition: Written, electronic, or phone/text-prompted food diaries, 24-hour recall, smartphone tracking applications Physical Activity: Pedometers or other wearable activity monitors 	Mental & Behavioral Health	<ul style="list-style-type: none"> Depression: Monitor for symptoms; if ≥12 years old evaluate annually using a formal self-report tool Other mental health: bullying, anxiety, abuse, ADHD Disordered eating: skipping meals, using diet pills/laxatives, inducing vomiting, restricting intake, binge-eating, etc. 	<ul style="list-style-type: none"> Overall: Pediatric Symptom Checklist Depression: Patient Health Questionnaire (PHQ 2 or 9) Anxiety: General Anxiety Disorder (GAD-7) or Screen for Child Anxiety Related Disorders (SCARED) assessments ADHD: Vanderbilt ADHD Rating Scales (VADRS) Disordered eating: Table 2, AAP Clinical report, "Identification and Management of Eating Disorders in Children and Adolescents"
Components	Tools												
Social Determinants of Health	<ul style="list-style-type: none"> Food security, economic security, & other social determinants of health (e.g., ACES) Safe Environment for Every Kid (SEEK) Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool 												
Individual/Family Lifestyle Behavior	<ul style="list-style-type: none"> Nutrition: eating out, sugar-sweetened beverages, portions, snack habits Physical activity: motivation/knowledge/competence to engage in physical activity Recreational screen time Sleep 	<ul style="list-style-type: none"> Overall: MaineHealth Let's Go! 5-2-1-0-Healthy-Habits-Questionnaires Nutrition: Written, electronic, or phone/text-prompted food diaries, 24-hour recall, smartphone tracking applications Physical Activity: Pedometers or other wearable activity monitors 											
Mental & Behavioral Health	<ul style="list-style-type: none"> Depression: Monitor for symptoms; if ≥12 years old evaluate annually using a formal self-report tool Other mental health: bullying, anxiety, abuse, ADHD Disordered eating: skipping meals, using diet pills/laxatives, inducing vomiting, restricting intake, binge-eating, etc. 	<ul style="list-style-type: none"> Overall: Pediatric Symptom Checklist Depression: Patient Health Questionnaire (PHQ 2 or 9) Anxiety: General Anxiety Disorder (GAD-7) or Screen for Child Anxiety Related Disorders (SCARED) assessments ADHD: Vanderbilt ADHD Rating Scales (VADRS) Disordered eating: Table 2, AAP Clinical report, "Identification and Management of Eating Disorders in Children and Adolescents" 											
Endocrine	Polyuria, polydipsia												
GYN	Oligomenorrhea, dysfunctional uterine bleeding												
Orthopedic	Hip, thigh or groin pain, painful or uneven gait, knee pain, foot pain, back pain, proximal muscle wasting												
Mental health	Sadness, depression, anhedonia, body dissatisfaction, school avoidance, poor self-image, impulse eating, distractibility, hyperactivity, purging, restricting intake, binge-eating, night eating, flat affect												
Urinary	Nocturia, enuresis												
Dermatologic	Rash, darkened skin on flexural surfaces, pustules, abscesses, hirsutism in females, flesh-colored striae, purplish striae, skin fold irritation												
Neurologic	AM headache, daytime sleepiness, persistent headache												

Conduct a Focused Physical Exam & Obtain Labs

Relevant Physical Exam Findings		Recommended Labs			
		Overweight		Obesity	
		<10y	≥10y	<10y	≥10y
Vital signs	Anthropometric				
• Hypertension	• Changes in height velocity				
• Increased heart rate	• Changes in weight gain				
Gastrointestinal	Genitourinary				
• Hepatomegaly	• Buried penis				
HEENT	Chest				
• Papilledema	• Gynecomastia				
• Dental caries	• Cervicodorsal hump				
• Tonsillar hypertrophy					
Musculoskeletal	Skin				
• Gait	• Acanthosis				
• Lordosis	• Hirsutism/acne				

Test	Overweight <10y	Overweight ≥10y	Obesity <10y	Obesity ≥10y
Fasting lipid panel ^a		✓	⚠	✓
FPG, OGTT, or HgbA1C ^b		⚠ ^c	⚠ ^c	✓
ALT ^c				✓

^a - Pediatricians & other pediatric health care providers [click here](#) ^b - Pediatricians & other pediatric health care providers [click here](#)
^c - If risk factors present for Prediabetes/Diabetes see back for more information on risk & work-up
^d - If risk factors present for Non Alcoholic Fatty Liver Disease see back for more information on risk & work-up

Talking Points: Engaging Family in Diagnostics & Treatment

- There is nobody more important to the health of your child than you; I want to partner with you to help (patient name) work towards improved health
- I am concerned that (patient's name) weight might be having an impact on their physical body and their emotional well-being.

Common Obesity-related Comorbidities: Risk Factors

Blount Disease	Risk Factors: Family history of Blount Disease, ambulation Disparities in Prevalence: non-Hispanic Black, Hispanic p Presentation: Leg or knee pain, abnormal gait with bow Diagnostic work-up: Obtain plain films (long leg AP and precurvatum)
Depression	Risk Factors: Personal or family history of depression Presentation: Irritability, fatigue, insomnia, excess Diagnostic work-up: Screen for depression with depression, anhedonia, body dissatisfaction, schoo
Dyslipidemia	Risk Factors: Cigarette use, hypertension (HTN) Presentation: Nothing specific Diagnostic work-up: Obtain fasting lipid pa
Hypertension (HTN)	Risk Factors: ACES, sodium/salt intake, ph Disparities in Prevalence: non-Hispanic B Presentation: Nothing specific Diagnostic work-up: Conduct routine b
Idiopathic Intracranial Hypertension (IIH)*	Risk Factors: Females of child-bearing Presentation: Persistent/progressiv Diagnostic work-up: *Urgent con
Nonalcoholic Fatty Liver Disease (NAFLD)	Risk Factors (Diagnosis): Male se Risk Factors (Severe Disease/P): Disparities in Prevalence: His Presentation: Asymptomatic Diagnostic work-up: Obtain
Obstructive Sleep Apnea (OSA)	Risk Factors: Tonsillar hyp Presentation: Frequent sn Diagnostic work-up: F

Clinical Flow: Assessment and Evaluation

- Screening
- Diagnosis
- Evaluation



Treatment Recommendations

Comprehensive Obesity Treatment

KAS 9. Pediatricians and other PHCPs should treat overweight (BMI \geq 85th percentile to $<$ 95th percentile) and obesity (BMI \geq 95th percentile) in children and adolescents, following the principles of the medical home and the chronic care model, using a family-centered and nonstigmatizing approach that acknowledges obesity's biologic, social, and structural drivers.

Provide the most intensive longitudinal treatment in the medical home



Provide or ensure ongoing medical evaluation & monitoring.

What is happening with this patient and family physically, emotionally, and socially?



Develop & implement an individualized comprehensive treatment plan, using evidence-based strategies.

What can help the patients & family develop & reach treatment goals and treat comorbidities?



Tailor treatment as needed.

What else is needed to support the patient & family's immediate needs & longitudinal treatment progress?



Serve as medical home.

What care coordination and/or advocacy does this patient/family need?



PCP & PHCP Evidence-Based Toolbox



Motivational Interviewing



Intensive Health Behavior & Lifestyle Treatment



Pharmacotherapy



Surgery

Motivational Interviewing

KAS 10. Pediatricians and other PHCPs should use motivational interviewing (MI) to engage patients and families in treating overweight (BMI \geq 85th percentile to $<$ 95th percentile) and obesity (BMI \geq 95th percentile).

Intensive Health Behavior and Lifestyle Treatment

KAS 11. Pediatricians and other PHCPs should provide or refer children 6 y and older (Grade B) and may provide or refer children 2 through 5 y of age (Grade C) with overweight (BMI \geq 85th percentile to $<$ 95th percentile) and obesity (BMI \geq 95th percentile) to intensive health behavior and lifestyle treatment. Health behavior and lifestyle treatment is more effective with greater contact hours; the most effective treatment includes 26 or more hours of face-to-face, family-based, multicomponent treatment over a 3- to 12-mo period.

More about IHBLT



WHO

- Patient & family
- Multidisciplinary treatment team

WHEN

- Upon diagnosis



WHAT

- Health education
- Skill building
- Behavior modification & counseling



FORMAT

- Group
- Individual, or
- Both



WHERE

- Healthcare setting
- Community-based setting with linkage to medical home



DOSAGE

- Longitudinal (3-12 months long)
- At least 26 contact hours



CHANNEL

- Face-to-face or
- Virtual



When IHBLT is not available, PCPs should...

Deliver the best available intensive treatment to all children with overweight and obesity.

Build collaborations with other specialists and programs in their communities.

Pharmacotherapy

KAS 12. Pediatricians and other PHCPs should offer adolescents 12 y and older with obesity (BMI \geq 95th percentile) wt loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment.

Consensus Recommendation: Pediatricians and other PHCPs may offer children ages 8 through 11 y of age with obesity weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment.

Metabolic and Bariatric Surgery

KAS 13: Pediatricians and other PHCPs should offer referral for adolescents 13 y and older with severe obesity (BMI \geq 120% of the 95th percentile for age and sex) for evaluation for metabolic and bariatric surgery to local or regional comprehensive multidisciplinary pediatric metabolic and bariatric surgery centers.

Criteria for Metabolic and Bariatric Surgery


TABLE 20

Criteria for Pediatric Metabolic and Bariatric Surgery⁷³³


Weight Criteria	Criteria for Comorbid Conditions
Class 2 obesity, BMI ≥ 35 kg/m ² or 120% of the 95th percentile for age and sex, whichever is lower	Clinically significant disease; examples include but are not limited to T2DM, IIH, NASH, Blount disease, SCFE, GERD, obstructive sleep apnea (AHI >5), cardiovascular disease risks (HTN, hyperlipidemia, insulin resistance), depressed health-related quality of life.
Class 3 obesity, BMI ≥ 40 kg/m ² or 140% of the 95th percentile for age and sex, whichever is lower	Not required but commonly present.

AHI, apnea-hypopnea index.

Putting it all Together



Medical Home



Longitudinal comprehensive patient-centered obesity treatment coordinated in the medical home

Adjunct tools to leverage where appropriate and in conjunction with foundational elements

Pharmacotherapy



Surgery



Foundational (Concurrent Core Elements)

Provision or referral to intensive Health Behavior and Lifestyle (HB&L) treatment (>=26 contact hours over 3-12 months)

Use of MI for shared decision making & ongoing behavioral counseling

Ongoing assessment of individual, social and contextual risk factors and evaluation for comorbidities & comorbidity treatment



Layer in multi-disciplinary care & community resources as available and tailored to patient/family strengths and needs.



Limitations and Challenges

Evidence Gaps and Future Research Needs

Important areas of uncertainty for pediatricians

- Duration of treatment effects on weight & comorbidities
- Heterogeneity of treatment effects
- SDS, SDOH, special populations, obesity severity
- Impact of specific components in multicomponent programs

Contributions of Specific Strategies are Unknown

Specific strategies

- Reduce sugar-sweetened beverage
- Use Choose My Plate
- Moderate to vigorous physical activity
- Reduce sedentary behavior
- Eat breakfast
- 5 2 1 0
- Ensure appropriate sleep



Nutrition




Physical Activity



Behavior Change



IHBLT



More Research Gaps

- **Epidemiology:** predictors of severe obesity; costs
- **Measurement:** alternatives to BMI in primary care; relation of BMI change with comorbid conditions
- **Risk factors:** biologic, such as maternal obesity; environmental, such as food insecurity
- **Comorbidities:** when and how often to evaluate; role of SDOH on comorbidity development, especially among minority populations

Implementation Barriers

- Healthcare infrastructure and capacity limitations, especially facing primary care pediatricians
- Coverage
- Burden on family to participate in IHBLT
- Skill set of providers who use medications



Advocacy Recommendations

Implementation and Advocacy Recommendations for Healthcare

- Coverage of **comprehensive** obesity prevention, evaluation, and treatment
- Multisector partnership to **expand access** to evidence-based pediatric obesity treatment programs
- CDS systems to aid in managing children and adolescents with obesity
- Improved education and training opportunities for practicing providers and in preprofessional schools and residency/fellowship programs

Implementation and Advocacy Recommendations

- Accelerate progress in prevention and treatment of obesity through **policy change within and beyond the health care sector to improve the health and well-being of children**
- Targeted policies are needed to purposefully address the **structural racism** in our society that drives the alarming and persistent disparities in childhood obesity and obesity-related comorbidities



AAP Clinical Implementation Resources

AAP Clinical Implementation Resources




**Self-Paced CME
Modules**



**Quality
Improvement
Opportunities**



**Clinical Decision
Support Tools**



**Coding
Reference
Card**



FHIR Resource



**Multimedia
Assets**



**Family
Resources**

Clinician Resources

Clinical Flow: Treatment and Approach in Primary Care Office Treatment (How – Part 2)

- Suggested treatment approaches
- Strategies to intensify treatment
- Pediatric'an's' toolbox of treatment options
- Medication considerations
- Support on interpreting lab results

Obesity Treatment & Approach in the Primary Care Office

Consistent with the 2023 AAP Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Overweight & Obesity (CPG) & associated algorithms. [#] Denotes content directly quoted or paraphrased from the CPG. * Denotes expert opinion.

Obesity Treatment Principles[#]

- Evidence based obesity treatment is effective and does not cause harm.
- Treat patients with overweight and obesity promptly, using the most intensive comprehensive obesity treatment available.
- Treat obesity concurrently with any comorbidities.
- Use a non-stigmatizing approach to treatment and shared decision making, following principles of the medical home and chronic care model.
- Evidence-based treatment strategies include: motivational interviewing (MI), intensive health behavior and lifestyle treatment (IHBLT), pharmacotherapy and surgery. (See additional information on Page 2.)

Key Aspects of Comprehensive Obesity Treatment[#]

Obesity is a complex chronic disease that requires a holistic patient-centered approach. Ensure that these elements are happening for your patient either within your office or via referrals you coordinate.

- Provide or ensure ongoing medical evaluation & monitoring**
 - What is happening with this patient and family physically, emotionally, and socially?
- Develop & implement an individualized comprehensive treatment plan, using evidence-based strategies (Refer to Page 2).**
 - What can help the patient & family develop & reach treatment goals and treat comorbidities?
- Tailor treatment as needed (See below & page 2).**
 - What else is needed to support the patient & family's immediate needs & longitudinal treatment progress?
- Serve as medical home**
 - What care coordination and/or advocacy does this patient/family need?

Role of the Pediatric Healthcare Provider (PHCP) +

The PHCP plays a critical role in supporting all patients and families in comprehensive obesity treatment and ensuring ongoing continuity of care, regardless of treatment scenario.

Treatment Scenarios	Role of PHCP		
	Provide Medical Evaluation & Monitoring	Deliver, Support & Refine Obesity Treatment Plan	Serve as Medical Home
Patient provided with most intensive obesity treatment possible within primary care	✓*	✓*	✓
Patient referred to community or healthcare partner for IHBLT	✓	✓	✓
Patient referred to pediatric weight management specialty program			✓

* Consider seeing patient again at the midpoint and conclusion of the IHBLT program or a minimum of every 3 months unless taking weight loss medication or has comorbid condition that requires more frequent visits.
*Ideally see at least monthly. Increase as needed or desired by patient or if more intensive medical monitoring is required.

Suggested Approach to Treatment in Your PCP Office +

Below are example treatment visit structures that align with CPG recommendations. Note: they are not the only ways to implement CPG recommendations.

Initial Overweight & Obesity Treatment Visit	Ongoing Overweight & Obesity Treatment Visit
Goals: Finish gathering important information, assess motivation & develop tailored treatment plan <ul style="list-style-type: none"> • Cover any items missed in well visit and/or address concerns • Assess any changes in patient history or medical status • Review labs & diagnostic test results • Discuss comorbid conditions, if relevant • Assess readiness and motivation • Collaboratively develop individualized treatment plan (using evidence-based tools: MI, IHBLT, pharmacotherapy, & surgery) • Agree to meet again in a month & connect to relevant community resources Operational Tips: <ul style="list-style-type: none"> • Plan for at least a 45-60 minute visit. Consider time-based billing codes: 99204-99205 (new patient) and 99215 (established patient). • Schedule within 1 month of well visit. 	Goals: Support family in their treatment plan, continue medical monitoring & refine treatment plan as needed <ul style="list-style-type: none"> • Monitor BMI • Assess any changes in patient history or medical status • Treat comorbid conditions • Use MI to support behavioral goals • Monitor progress with IHBLT • Monitor pharmacotherapy & surgery if applicable • Refine treatment plan as needed • Coordinate care & connect to relevant community resources Operational Tips: <ul style="list-style-type: none"> • Plan for at least a 20-25 minute visit at least monthly if providing IHBLT. Consider time-based billing codes: 99213-99215 (established patients). • If IHBLT is external, consider seeing every 3 months or at midway & conclusion of program unless patient is on medication or has comorbid conditions.

Strategies to Intensify Care

(When no pediatric weight management specialty program or IHBLT is available)

PHCP Evidence Based Toolbox[#]

Motivational Interviewing: Use MI to engage patients and families in treating overweight and obesity.

Interpretation of Test Results[#]

NHLBI Criteria for Lipid Testing Results^A

Weight Loss Medication Use & Mechanism [#]	High (mg/DL)
PHCPs who prescribe weight loss medications should have knowledge of the patient selection criteria, medication efficacy, adverse effects, and follow-up monitoring guidelines. Injectables may require additional teaching. PHCPs may choose to refer to pediatric obesity experts or treatment centers for prescribing weight loss medication. There is no evidence to support the use of weight loss medications alone. Medication should be	≥200
	≥130
	≥100
	≥145

Side Effects

Side effects are dose dependent and include nausea, flatulence, etc.	≥100
Side effects are dose dependent and include nausea, flatulence, etc.	≥130
Side effects are dose dependent and include nausea, flatulence, etc.	≥145

Patient and Family Resources



- Updated content for HealthyChildren.org and fact sheet formats
- Goal sheets



The image shows a "My Goal Sheet" form. It has a blue header with the title "My Goal Sheet". Below the header, there are two columns: "NAME" and "TODAY'S DATE". The main body of the form is divided into two large sections: "MY GOAL" and "IDEAS TO HELP ME ACHIEVE MY GOAL". At the bottom of the form, there is a section labeled "OTHER NOTES:". The form is designed to help patients and families track their goals and the strategies they use to achieve them.



www.aap.org/obesitycpg



Copyright protected material

NCCOR
CONNECT & EXPLORE

THANK YOU!



Email

obesity@aap.org

Institute for Healthy Childhood Weight Website

<https://ihcw.aap.org>

Clinical Practice Guideline for the Evaluation
and Treatment of Children and Adolescents
with Obesity Website

<https://www.aap.org/obesitycpg>


Twitter

@AAPHealthyWT



CDC Extended BMI-for-age growth charts

Cynthia Ogden, PhD, MRP
NHANES Analysis Branch Chief


March 28, 2023



December 15, 2022
Data source: National Health Examination Survey and National Health and Nutrition Examination Survey.
Developed by National Center for Health Statistics in collaboration with National Center for Chronic Disease Prevention and Health Promotion, 2022.



December 15, 2022
Data source: National Health Examination Survey and National Health and Nutrition Examination Survey.
Developed by National Center for Health Statistics in collaboration with National Center for Chronic Disease Prevention and Health Promotion, 2022.



Key Points


- Prevalence of childhood obesity has increased over the past 40 years
- 2000 CDC body mass index (BMI)-for-Age Growth Charts do not extend to BMIs high enough for children and adolescents with extreme BMIs
- New tool available: CDC Extended BMI-for-Age Growth Charts to track growth for children & adolescents with severe obesity

Extended BMI-for-Age Growth Charts

Why?

Why Were New BMI Growth Charts Created?

Obesity prevalence among US children and adolescents



Severe obesity prevalence:

1971-74: 1.0%

to


2017-18: 6.1%

NOTE: Obesity is body mass index (BMI) at or above the 95th percentile from the sex-specific BMI-for-age 2000 CDC Growth Charts.
SOURCES: National Center for Health Statistics, National Health Examination Surveys II (ages 6-11), III (ages 12-17); and National Health and Nutrition Examination Surveys (NHANES) I-III, and NHANES 1999-2000, 2001-2002, 2003-2004, 2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014, 2015-2016, and 2017-2018.

<https://www.cdc.gov/nchs/data/hestat/obesity-child-17-18/obesity-child.htm>

CDC Effort To Evaluate Alternative BMI Metrics

- Wanted a single, continuous metric
- Workshop with CDC/NIH/academia in 2018
- Reviewed several alternatives:
 - BMI (untransformed)
 - % of 95th percentile
 - BMI units from the median (adjusted and unadjusted)
 - Percent from the median (adjusted and unadjusted)
 - Modified BMI z-scores/percentiles
 - used for identifying implausible values
 - Extended BMI z-scores/percentiles
 - NEW! Created by NCHS



Hales *et al.* Vital Health Stat 2022

Extended BMI-for-Age Growth Charts What?

What is New?


- Includes 4 additional percentile curves above the 95th percentile
 - 98th, 99th, 99.9th, and 99.99th percentiles
- Can plot BMI up to 60 kg/m²
- Includes line with 120% of the 95th percentile (severe obesity threshold)
- Shading provides a visual aid for discussing very high BMI with children and families

Boys: Ages 2–20 years

Body mass index-for-age percentiles

NAME _____

RECORD # _____




Girls: Ages 2–20 years

Body mass index-for-age percentiles

NAME _____

RECORD # _____



Extended BMI Z-scores and Percentiles: Data Source

Combines all children and adolescents with obesity 1963-2016

Children in CDC 2000 Reference
Population with obesity

Primarily 1963-1980


+

Additional children and
adolescents with obesity

1988-2016



Extended BMI Z-scores and Percentiles: Method

- BMI distribution above the 95th percentile modelled
- Did not shift whole distribution
- Preserved BMI z-scores and percentiles up to the 95th percentile



What Does Not Change?

2000 CDC growth charts and BMI Categories



BMI Category	BMI Range
Overweight	85 th to <95 th percentile
Obesity	≥95 th percentile
Severe Obesity	≥120% of the 95 th percentile or ≥35 kg/m ²

Advantages of Extended BMI Z-scores and Percentiles

- Single metric for seamless use across all BMIs and weight categories
 - Familiar
- Reference curves/percentiles based on nationally representative data
 - Unlike other metrics

Website with Additional Resources



National Center for Health Statistics

CDC > National Center for Health Statistics > Growth Charts > CDC Growth Charts

CDC Extended BMI-for-Age Growth Charts

[Print](#)


In the US, the prevalence of obesity and severe obesity has increased since 1980, and in 2017-2018 more than 4.5 million children and adolescents had severe obesity. The 2000 CDC BMI-for-age growth charts, based on data from 1963-1980 for most children, do not extend beyond the 97th percentile. So, CDC developed new percentiles to monitor very high BMI values. These extended percentiles are based on data for children and adolescents with obesity – including from 1988-2016 – thus increasing the data available in the reference population. See the [report on alternative BMI metrics](#) for more information.

<https://www.cdc.gov/growthcharts/extended-bmi.htm>

CDC Extended BMI-for-Age Growth Charts



For Healthcare professionals



Data File with LMS and Sigma Parameters



Computer Program






Cynthia L Ogden, PhD
cogden@cdc.gov

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Thank you to Drs. Aly Goodman and Craig Hales for some slides.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



Q & A

ANNOUNCEMENTS



Upcoming Connect & Explore Webinar



NCCOR
CONNECT & EXPLORE
WEBINAR SERIES

CONNECT & EXPLORE

Cooperative Extension's National Framework for Health Equity and Well-Being: Implementation and Intersections with NCCOR Partners

THURSDAY
APRIL 27, 2023

9AM PT 10AM MT 11AM CT 12PM ET



New Publication

- NCCOR Annual Report 2022: Connecting Research to Communities
 - Highlights NCCOR accomplishments last year
 - Read at www.nccor.org



New Publication

- National Collaborative on Childhood Obesity Research Efforts to Advance Childhood Obesity Research: Progress and Next Steps
 - Amanda S. Sharfman, David Berrigan, Deborah A. Galuska, Laura Kettel Khan, Ellen W. Stowe, Jill Reedy
 - American Journal of Preventive Medicine
 - March 2023



**Sign up for
NCCOR
Student Hub!**


→ nccor.org/e-newsletter

Check out the student hub webpage!



Have you used any of NCCOR's tools?

Let us know at nccor@fhi360.org
and we may feature you in our next webinar!



FOLLOW US *on*
SOCIAL MEDIA



@NCCCOR

f /NCCCOR.ORG



FURTHER QUESTIONS?

Email the NCCOR Coordinating Center
nccor@fhi360.org

